Sarepta Therapeutics Inc.’s controversial gene therapy for a rare muscle condition will remain available in the US with a strict new warning about potentially deadly liver injuries, a regulatory decision that removes the risk it would be pulled from the market.
www.bloomberg.com
#Sareptas #Elevidys #Remain #Market #FDA #Warning
Sarepta’s Elevidys to Remain on Market With New FDA Warning
